TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3922936

Group type: EXPERIMENTAL
Intervention: Aztreonam (1 or 2 g intramuscular injections for ten days)
Number of subjects: 36
Study: 31699946

Group type: EXPERIMENTAL
Intervention: Renogen (biosimilar EPO)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Eprex (originator EPO)
Number of subjects: 45
Study: 29193747

Group type: EXPERIMENTAL
Intervention: 2 mg cherry-flavored mini lozenge
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 4 mg cherry-flavored mini lozenge
Number of subjects: 43

Group type: COMPARATOR
Intervention: 2 mg mint-flavored mini lozenge
Number of subjects: 43

Group type: COMPARATOR
Intervention: 4 mg mint-flavored mini lozenge
Number of subjects: 43
Study: 26354927

Group type: EXPERIMENTAL
Intervention: Procarbazine/lomustine/vincristine (PCV) chemotherapy
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Targeted next-generation sequencing (NGS)
Number of subjects: 139

Group type: COMPARATOR
Intervention: 1p/19q codeleted tumors
Number of subjects: 139
Study: 23761303

Group type: EXPERIMENTAL
Intervention: Zoledronate 1 mg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Zoledronate 2.5 mg
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Zoledronate 5 mg
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 22176842

Group type: EXPERIMENTAL
Intervention: Fax to Quit plus Enhanced Academic Detailing (F2Q+EAD)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Fax to Quit‐Only (F2Q‐Only)
Number of subjects: 49
Study: 19952950

Group type: EXPERIMENTAL
Intervention: Low-dose interferon-alpha 2a
Number of subjects: 850
Study: 17505437

Group type: EXPERIMENTAL
Intervention: TISSEEL VH S/D
Number of subjects: 100

Group type: COMPARATOR
Intervention: TISSEEL VH
Number of subjects: 100
Study: 16177249

Group type: EXPERIMENTAL
Intervention: 2 g of azithromycin orally
Number of subjects: 328

Group type: COMPARATOR
Intervention: 2.4 million units of penicillin G benzathine intramuscularly
Number of subjects: 328
Study: 11929348

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate combination (SFC) 50/100microg, administered twice daily via inhaler for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 100microg, administered twice daily via inhaler for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SFC
Number of subjects: 0

Group type: COMPARATOR
Intervention: FP
Number of subjects: 0
Study: 9683114

Group type: EXPERIMENTAL
Intervention: 2-hour incontinence care schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4-hour incontinence care schedule
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incontinence care intervention
Number of subjects: 0
Study: 8006262

Group type: COMPARATOR
Intervention: Monophasic waveform
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Biphasic waveform
Number of subjects: 21
Study: 2842140

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31712950

Group type: EXPERIMENTAL
Intervention: Exercise prehabilitation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 22
Study: 28604133

Group type: EXPERIMENTAL
Intervention: Topical cetirizine 1%
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 26892849

Group type: EXPERIMENTAL
Intervention: Eye movement desensitisation and reprocessing (EMDR) therapy (12 hours total: 3×60 min planning/preparation followed by 6×90 min desensitisation/reprocessing)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Stabilisation therapy (12 hours total: 12×60 min)
Number of subjects: 72
Study: 24188252

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 23842081

Group type: EXPERIMENTAL
Intervention: Milk-fat from mountain-pasture grazing cows (G)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conventional Danish butter (C)
Number of subjects: 38
Study: 21731996

Group type: EXPERIMENTAL
Intervention: Intrathecal bupivacaine with midazolam (3 mL 0.5% bupivacaine and 0.4 mL (2 mg) midazolam)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intrathecal bupivacaine without midazolam (3 mL 0.5% bupivacaine with 0.4 mL saline)
Number of subjects: 100
Study: 19362014

Group type: EXPERIMENTAL
Intervention: Cohen blocker
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Arndt blocker
Number of subjects: 48

Group type: COMPARATOR
Intervention: Left double-lumen tube (DLT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cohen blocker (left bronchus occlusion)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cohen blocker (right bronchus occlusion)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All blockers
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cohen blocker and Arndt blocker
Number of subjects: 48

Group type: COMPARATOR
Intervention: DLT
Number of subjects: 48
Study: 17081282

Group type: EXPERIMENTAL
Intervention: Intravenous trace element supplements (copper 2.5 to 3.1 mg/day, selenium 315 to 380 µg/day, zinc 26.2 to 31.4 mg/day) for 8 to 21 days
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Intravenous trace element supplements
Number of subjects: 41
Study: 15471833

Group type: EXPERIMENTAL
Intervention: 99mTc‐labeled ethylene dicysteine (EC) C225 administered before 20 mg test dose
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 99mTc‐labeled ethylene dicysteine (EC) C225 administered after 400 mg/m2 loading dose of unlabeled C225
Number of subjects: 6
Study: 11299845

Group type: EXPERIMENTAL
Intervention: Doxorubicin followed by Docetaxel (A->T->CMF)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Docetaxel followed by Doxorubicin (T->A->CMF)
Number of subjects: 34
Study: 9266270

Group type: EXPERIMENTAL
Intervention: Ampicillin (1 g)/Sulbactam (0.5 g)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Cefotiam (2 g)
Number of subjects: 81
Study: 8119065

Group type: EXPERIMENTAL
Intervention: Partial ileal bypass operation (surgery-assigned group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diet treatment (control-assigned group)
Number of subjects: 0
Study: 6480455

Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO) at 15.5 gm/M2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO) at 13.5 gm/M2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Misonidazole (MISO) at 17.5 gm/M2
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEXA) 2 mg t.i.d. during treatment
Number of subjects: 16
Study: 30273185

Group type: EXPERIMENTAL
Intervention: Selective nerve root block (SNRB)
Number of subjects: 233
Study: 30125052

Group type: EXPERIMENTAL
Intervention: Epanova 4 g daily
Number of subjects: 13086

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13086
Study: 27031491

Group type: EXPERIMENTAL
Intervention: 40 Hz sound stimulation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Visual stimulation using DVDs
Number of subjects: 18
Study: 25240821

Group type: EXPERIMENTAL
Intervention: Ramucirumab plus paclitaxel
Number of subjects: 665

Group type: COMPARATOR
Intervention: Placebo plus paclitaxel
Number of subjects: 665
Study: 23031850

Group type: EXPERIMENTAL
Intervention: Maternal education, household possessions, infant birth weight, child HIV infection, male sex
Number of subjects: 2387

Group type: EXPERIMENTAL
Intervention: Preterm infants
Number of subjects: 2387

Group type: EXPERIMENTAL
Intervention: Low Apgar score at birth
Number of subjects: 2387

Group type: EXPERIMENTAL
Intervention: Interventions to improve maternal education and nutritional status, reduce mother-to-child transmission of HIV, and increase birth weight
Number of subjects: 2387
Study: 20735822

Group type: EXPERIMENTAL
Intervention: Participatory Ergonomics (PE)
Number of subjects: 81
Study: 17625416

Group type: EXPERIMENTAL
Intervention: Laparoscopic colposuspension
Number of subjects: 491

Group type: COMPARATOR
Intervention: Open colposuspension
Number of subjects: 491
Study: 17196275

Group type: EXPERIMENTAL
Intervention: Xuezhikang (1200 mg/d)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 15048162

Group type: EXPERIMENTAL
Intervention: Limiting tidal volume in acute lung injury or acute respiratory distress syndrome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early goal directed therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant human activated protein C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate doses of steroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tight control of blood sugar
Number of subjects: 0
Study: 10910421

Group type: EXPERIMENTAL
Intervention: Nortriptyline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 0
Study: 8725851

Group type: EXPERIMENTAL
Intervention: Miglitol (50 mg three times daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Miglitol
Number of subjects: 20
Study: 1340780

Group type: EXPERIMENTAL
Intervention: Ephedrine 50 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ephedrine 25 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (0.9% sodium chloride)
Number of subjects: 30
Study: 6726466

Group type: EXPERIMENTAL
Intervention: Maternal pyridoxine X HCl (PN‐HCl) supplementation at 7.5 mg or more
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal pyridoxine X HCl (PN‐HCl) supplementation at 7.5 mg and greater
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal pyridoxine X HCl (PN‐HCl) supplementation at 7.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal vitamin B-6 supplementation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin B-6 intake between 5.5 and 7.6 mg/day (diet plus supplement as pyridoxine equivalents)
Number of subjects: 0
Study: 31174397

Group type: EXPERIMENTAL
Intervention: Combined exercise program including stretching of hamstrings and progressive resistance exercise (PRE) targeting the lower extremities, 16 weeks (3 sessions per week) followed by a 16-week maintenance program (1 session per week)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Care as usual (comparison group)
Number of subjects: 37
Study: 28082159

Group type: COMPARATOR
Intervention: Lecture slides (LG)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Prosections (PG)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Radiology images (RG)
Number of subjects: 73
Study: 24707921

Group type: EXPERIMENTAL
Intervention: M1 HMCAS
Number of subjects: 126

Group type: COMPARATOR
Intervention: NHMCAS
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Distal HMCAS
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Hyperdense M2
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: HMCAS proximal
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: HMCAS full length
Number of subjects: 126
Study: 23866945

Group type: EXPERIMENTAL
Intervention: POE-POP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 21346160

Group type: EXPERIMENTAL
Intervention: Flexion-extension method
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conventional method (Control)
Number of subjects: 96
Study: 19332958

Group type: EXPERIMENTAL
Intervention: Telmisartan 80 mg plus amlodipine 10 mg
Number of subjects: 1078

Group type: COMPARATOR
Intervention: Amlodipine 10 mg (monotherapy)
Number of subjects: 1078

Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg plus amlodipine 10 mg
Number of subjects: 1078
Study: 16537682

Group type: EXPERIMENTAL
Intervention: saline/ghrelin infusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: l-arginine/saline
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: l-arginine/ghrelin
Number of subjects: 9

Group type: COMPARATOR
Intervention: saline/saline
Number of subjects: 9

Group type: COMPARATOR
Intervention: saline/ghrelin
Number of subjects: 9
Study: 12683264

Group type: EXPERIMENTAL
Intervention: Atypical antipsychotics (except amisulpride)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atypical antipsychotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risperidone, Olanzapine, Quetiapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clozapine
Number of subjects: 0
Study: 10882582

Group type: EXPERIMENTAL
Intervention: Saquinavir (SQV)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Indinavir (IDV)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Statistical methods (cluster analysis, recursive partitioning, linear discriminant analysis)
Number of subjects: 72
Study: 8622332

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol (800 IU daily for first 546 patients; 400 IU daily for remainder)
Number of subjects: 2002

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2002
Study: 1391111

Group type: COMPARATOR
Intervention: Conventional diet administered to 21 patients
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Commercial enteral diet administered to 28 patients
Number of subjects: 49
Study: 6399448

Group type: EXPERIMENTAL
Intervention: Individualized imagery of drinking situations associated with painful electric shock
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individualized imagery of drinking situations associated with sham shock
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General treatment program for alcoholism including relaxation training
Number of subjects: 0
Study: 29768093

Group type: EXPERIMENTAL
Intervention: Kipping Pull-Up (KPU)
Number of subjects: 11
Study: 29402303

Group type: EXPERIMENTAL
Intervention: Laparoscopic ventral mesh rectopexy (LVMR)
Number of subjects: 0
Study: 26031397

Group type: EXPERIMENTAL
Intervention: Zinc acetate and chlorhexidine diacetate
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Zinc acetate and chlorhexidine diacetate with reduced amounts of mint and menthol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Zinc chloride and essential oil
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Zinc lactate, chlorhexidine and cetylpyridinium chloride
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 24568148

Group type: EXPERIMENTAL
Intervention: Myoelectric simulator training (direct grasping)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Myoelectric simulator training (indirect grasping)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Myoelectric simulator training (fixating)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Myoelectric simulator training (combination of tasks)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no practice)
Number of subjects: 31
Study: 22321357

Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel (Continuing Active subjects)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: 1.62% testosterone gel (Formerly Placebo subjects)
Number of subjects: 163
Study: 20061358

Group type: EXPERIMENTAL
Intervention: Intensive glucose control (haemoglobin A(1C) <6.0%)
Number of subjects: 10194

Group type: EXPERIMENTAL
Intervention: Standard glucose control (haemoglobin A(1C) 7.0-7.9%)
Number of subjects: 10194

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 10194
Study: 18004138

Group type: EXPERIMENTAL
Intervention: Venlafaxine 37.5 mg BID for 7 days followed by 75 mg BID for another 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15780963

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg daily
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 11813623

Group type: EXPERIMENTAL
Intervention: Chemohyperthermic peritoneal perfusion (CHPP)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Chemonormothermic peritoneal perfusion (CNPP)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 139
Study: 9744643

Group type: EXPERIMENTAL
Intervention: rBPI21 administered by continuous intravenous infusion for 48 hours in patients and healthy volunteers
Number of subjects: 0

Group type: COMPARATOR
Intervention: rBPI21 administered intravenously in rats after 60% or 80% hepatectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administered to healthy volunteers
Number of subjects: 0
Study: 8172096

Group type: EXPERIMENTAL
Intervention: Large amounts of endurance exercise (400 min/wk) + weight training (3 d/wk) + very-low-energy diet (3360-kJ/d)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Moderate amounts of endurance exercise (200 min/wk) + weight training (3 d/wk) + very-low-energy diet (3360-kJ/d)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no exercise) + very-low-energy diet (3360-kJ/d)
Number of subjects: 23
Study: 3054591

Group type: EXPERIMENTAL
Intervention: Combined treatment with preoperative radiotherapy (4 Gy for 5 days, total 20 Gy)
Number of subjects: 478

Group type: COMPARATOR
Intervention: Surgical treatment only
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Combined treatment with preoperative radiotherapy
Number of subjects: 478
Study: 30963229

Group type: EXPERIMENTAL
Intervention: Monopolar enucleation of the prostate (MEP)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 134

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: MEP
Number of subjects: 134
Study: 31072710

Group type: EXPERIMENTAL
Intervention: Targeted therapeutic mild hypercapnia (TTMH) with target arterial carbon dioxide partial pressure between 50 and 55 mmHg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard carbon dioxide management (normocapnia)
Number of subjects: 30
Study: 28500492

Group type: EXPERIMENTAL
Intervention: Methylprednisolone 500 mg i.v.
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Paracetamol 4 g i.v.
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo i.v.
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: All groups (Methylprednisolone, Paracetamol, Placebo)
Number of subjects: 83
Study: 26135245

Group type: EXPERIMENTAL
Intervention: Investigational MenABCWY vaccine formulations (2 doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Investigational MenABCWY vaccine formulations (3 doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Investigational MenABCWY vaccines (2 or 3 doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Investigational MenABCWY vaccines
Number of subjects: 0
Study: 24094643

Group type: EXPERIMENTAL
Intervention: 100 kV 250 mAs with hybrid iterative reconstruction (iDose)
Number of subjects: 44

Group type: COMPARATOR
Intervention: 120 kV 250 mAs with filtered back projection (FBP)
Number of subjects: 44
Study: 21452294

Group type: EXPERIMENTAL
Intervention: Atacicept 150 mg weekly (with or without a 4-week loading period)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 311

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Atacicept (both groups)
Number of subjects: 311
Study: 17433756

Group type: EXPERIMENTAL
Intervention: Therapeutic taping
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control taping
Number of subjects: 15

Group type: COMPARATOR
Intervention: No taping
Number of subjects: 15
Study: 16024183

Group type: EXPERIMENTAL
Intervention: Isoflurane (0.1 and 0.2%)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.2 and 0.4%)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (N2O) (15 and 30%)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Vehicle (100% O2)
Number of subjects: 14
Study: 12900133

Group type: EXPERIMENTAL
Intervention: High-dose magnesium and low-dose lidocaine, infused over 3 days
Number of subjects: 32
Study: 10875098

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (ampicillin)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cervicovaginal fluid IL-6 measurement
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cervicovaginal fluid IL-8 measurement
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Neonatal infections
Number of subjects: 36
Study: 9104869

Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) followed by Aerobic Training (AT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 7956612

Group type: EXPERIMENTAL
Intervention: Propranolol (30-60 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2852692

Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP) 10 mg iv
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Domperidone (DMP) 10 mg iv
Number of subjects: 15
Study: 31354055

Group type: EXPERIMENTAL
Intervention: Intravenous glyburide
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 30489094

Group type: EXPERIMENTAL
Intervention: Self-reflection training
Number of subjects: 226

Group type: COMPARATOR
Intervention: Coping skills training
Number of subjects: 226
Study: 27875943

Group type: EXPERIMENTAL
Intervention: Thicker surfboards (higher volume)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Thinner surfboards (lower volume)
Number of subjects: 20
Study: 27537707

Group type: EXPERIMENTAL
Intervention: Thought Listing (TL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive Restructuring (CR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-Hoarding Community Controls (CC)
Number of subjects: 0
Study: 24750544

Group type: EXPERIMENTAL
Intervention: Adherence Therapy (AT)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Routine Care (RC)
Number of subjects: 76
Study: 22460947

Group type: EXPERIMENTAL
Intervention: Intensive consolidation therapy (high-dose cytarabine combined with amsacrine or daunorubicin)
Number of subjects: 315

Group type: COMPARATOR
Intervention: Standard consolidation and maintenance therapy (standard dose cytarabine and daunorubicin)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Intensive consolidation therapy
Number of subjects: 315

Group type: COMPARATOR
Intervention: Standard consolidation and maintenance therapy
Number of subjects: 315
Study: 18718816

Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation using the Heart Manual
Number of subjects: 26

Group type: COMPARATOR
Intervention: Hospital-based cardiac rehabilitation
Number of subjects: 26